( OTC-PINK:RXII, OTC-QB:RXII )

News from RXi Pharmaceuticals Corporation A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

21 Jun, 2017, 07:05 ET RXi Pharmaceuticals Announces Completion of Enrollment of Phase 1/2 Clinical Trial with RXI-109 for Retinal Scarring

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant...


12 Jun, 2017, 07:05 ET RXi Pharmaceuticals Announces the Initiation of its Consumer Testing Program with RXI-231

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


08 Jun, 2017, 07:05 ET RXi Pharmaceuticals to Present at the Marcum MicroCap Conference

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


07 Jun, 2017, 07:05 ET RXi Pharmaceuticals Corporation Announces the Appointment of Dr. Jonathan Freeman to its Board of Directors

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant...


23 May, 2017, 07:05 ET RXi Pharmaceuticals to Present at the 3rd Annual Immuno-Oncology BD&L and Investment Forum

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


22 May, 2017, 07:05 ET PCI Biotech and RXi Pharmaceuticals Extend Research Collaboration to the Field of Immuno-oncology

PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, and RXi Pharmaceuticals (NASDAQ: RXII) a biotechnology company focused on...


11 May, 2017, 07:05 ET RXi Pharmaceuticals Reports First Quarter 2017 Financial Results and Recent Corporate Highlights

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


04 May, 2017, 07:02 ET RXi Pharmaceuticals to Webcast First Quarter 2017 Financial Results on Thursday, May 11, 2017

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


02 May, 2017, 07:02 ET RXi Pharmaceuticals to Present at the Association for Research in Vision and Ophthalmology 2017 Annual Meeting

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


01 May, 2017, 07:02 ET RXi Pharmaceuticals Corporation Selected to Present at the Cavendish Global Health Impact Forum

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


25 Apr, 2017, 07:02 ET RXi Pharmaceuticals to Present at 19th Annual TIDES: Oligonucleotide and Peptides Therapeutics Conference

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant...


20 Apr, 2017, 07:02 ET RXi Pharmaceuticals to Present an Update on its Consumer Product Development Programs at the Society for Investigative Dermatology 76th Annual Meeting

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


18 Apr, 2017, 07:02 ET RXi Pharmaceuticals Announces New Chief Development Officer and Key Management Changes

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


31 Mar, 2017, 07:02 ET RXi Pharmaceuticals to Present at the American Association for Cancer Research Annual Meeting

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


30 Mar, 2017, 07:02 ET RXi Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results and Recent Corporate Highlights

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


28 Mar, 2017, 07:02 ET RXi Pharmaceuticals Granted Patent in Japan for Lead Clinical Candidate RXI-109

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


22 Mar, 2017, 07:02 ET RXi Pharmaceuticals to Present at the 5th Annual Cancer BioPartnering & Investment Forum

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


21 Mar, 2017, 07:02 ET RXi Pharmaceuticals to Present at the 2nd Annual Oligonucleotide and Peptide Therapeutics Conference

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


16 Mar, 2017, 07:02 ET RXi Pharmaceuticals to Webcast Fourth Quarter and Year End 2016 Financial Results on Thursday, March 30, 2017

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


14 Feb, 2017, 07:02 ET RXi Pharmaceuticals Appoints Medical Oncology Expert, Dr. James Griffin, to Scientific Advisory Board

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


08 Feb, 2017, 07:02 ET RXi Pharmaceuticals to Present at Leading Investor and Healthcare Conferences

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


09 Jan, 2017, 07:02 ET RXi Pharmaceuticals Completes Acquisition of MirImmune Inc. and Appoints New Chief Business Officer

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


26 Dec, 2016, 07:02 ET RXi Pharmaceuticals to Present at the 9th Annual Biotech Showcase™

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage company developing innovative therapeutics that address significant unmet medical...


21 Dec, 2016, 09:53 ET RXi Pharmaceuticals Announces Closing of $11.5 Million Underwritten Public Offering and Full Exercise of Over-allotment Option

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage company developing innovative therapeutics that address significant unmet medical...


16 Dec, 2016, 08:15 ET RXi Pharmaceuticals Announces Pricing of $10 Million Underwritten Public Offering

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage company developing innovative therapeutics that address significant unmet...